Assessing the Future of Inclisiran in Clinical, Pharmacy Settings

January 26, 2022

Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses projections for inclisiran’s use in clinical and pharmacy settings.

Pharmacy Times interviewed Norman Lepor, MD, a Los Angeles-based cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), on the burden of atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol management.

During the interview, Lepor discussed projections for the use of inclisiran in clinical and pharmacy settings.